Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: Communication from the SSC of the ISTH.

IF 5.5 2区医学 Q1 HEMATOLOGY

Journal of Thrombosis and Haemostasis Pub Date : 2025-07-18 DOI:10.1016/j.jtha.2025.07.014

Marta Brambilla, Emma C Josefsson, Sofia Ramstrom, Alessandro Di Minno, Matteo Nicola Dario Di Minno, Pradnya Gangatirkar, Diane Moujalled, Alessia Becchetti, Marie Lordkipanidzé, Marina Camera

{"title":"Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: Communication from the SSC of the ISTH.","authors":"Marta Brambilla, Emma C Josefsson, Sofia Ramstrom, Alessandro Di Minno, Matteo Nicola Dario Di Minno, Pradnya Gangatirkar, Diane Moujalled, Alessia Becchetti, Marie Lordkipanidzé, Marina Camera","doi":"10.1016/j.jtha.2025.07.014","DOIUrl":null,"url":null,"abstract":"Background: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet activation marker may be useful to improve thrombotic risk stratification. Therefore, we performed a meta-analysis investigating the association between levels of 14 such markers with CAD.Methods: PubMed, Web of Science and EMBASE were searched until November 2024. The primary endpoint was the difference in levels of 11-dehydro-thromboxane B2, 2,3-dinor-TXB2, β-thromboglobulin, sCD40L, glycocalicin, GPV, GPVI, matrix metalloproteinase-9 (MMP-9) and 2 , Platelet Factor 4 (PF4), sP-selectin, SCUBE1, serotonin and thrombospondin 1(TSP-1) between CAD patients and healthy subjects (HS) in plasma and/or serum. When possible, CAD patients were stratified into acute coronary syndrome (ACS) and chronic coronary disease (CCD). Standardized mean difference (SMD) was calculated.Results: Due to studies' heterogeneity, meta-analysis was performed for sCD40L, sGPV, MMP-9, PF4, sP-selectin, SCUBE1 and TSP-1. All markers but TSP-1 were significantly elevated in CAD patients versus HS. Differences in sCD40L and SCUBE1 were statistically significant only when plasma and serum studies were combined. When compared to HS the differences were bigger in ACS versus CCD for MMP-9 (SMD: 2.49 vs 0.49), PF4 (SMD: 2.01 vs 0.96), and sP-selectin (SMD: 1.81 vs 0.63). Publication bias was identified for sCD40L and in ACS for sP-selectin and PF4.Conclusions: The increased levels of sCD40L, sGPV, MMP-9, PF4, sP-selectin and SCUBE1 in CAD patients compared to HS provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtha.2025.07.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Given the role of platelets in coronary artery disease (CAD), assessment of a soluble platelet activation marker may be useful to improve thrombotic risk stratification. Therefore, we performed a meta-analysis investigating the association between levels of 14 such markers with CAD.

Methods: PubMed, Web of Science and EMBASE were searched until November 2024. The primary endpoint was the difference in levels of 11-dehydro-thromboxane B₂, 2,3-dinor-TXB₂, β-thromboglobulin, sCD40L, glycocalicin, GPV, GPVI, matrix metalloproteinase-9 (MMP-9) and 2 , Platelet Factor 4 (PF4), sP-selectin, SCUBE1, serotonin and thrombospondin 1(TSP-1) between CAD patients and healthy subjects (HS) in plasma and/or serum. When possible, CAD patients were stratified into acute coronary syndrome (ACS) and chronic coronary disease (CCD). Standardized mean difference (SMD) was calculated.

Results: Due to studies' heterogeneity, meta-analysis was performed for sCD40L, sGPV, MMP-9, PF4, sP-selectin, SCUBE1 and TSP-1. All markers but TSP-1 were significantly elevated in CAD patients versus HS. Differences in sCD40L and SCUBE1 were statistically significant only when plasma and serum studies were combined. When compared to HS the differences were bigger in ACS versus CCD for MMP-9 (SMD: 2.49 vs 0.49), PF4 (SMD: 2.01 vs 0.96), and sP-selectin (SMD: 1.81 vs 0.63). Publication bias was identified for sCD40L and in ACS for sP-selectin and PF4.

Conclusions: The increased levels of sCD40L, sGPV, MMP-9, PF4, sP-selectin and SCUBE1 in CAD patients compared to HS provide a rationale for designing new studies to address the potential of such molecules as biomarkers for thrombotic risk stratification.

查看原文本刊更多论文

冠状动脉疾病中体内血小板活化的生物标志物：系统回顾和荟萃分析：来自ISTH的SSC的信息

背景：考虑到血小板在冠状动脉疾病（CAD）中的作用，评估可溶性血小板活化标志物可能有助于改善血栓形成风险分层。因此，我们进行了一项荟萃分析，调查了14种此类标志物水平与CAD之间的关系。方法：检索至2024年11月的PubMed、Web of Science和EMBASE数据库。主要终点是冠心病患者与健康人群（HS）血浆和/或血清中11-脱氢血栓素B2、2,3-dinor- txb2、β-血栓球蛋白、sCD40L、糖钙素、GPV、GPVI、基质金属蛋白酶9 （MMP-9）和2、血小板因子4 （PF4）、sp -选择素、SCUBE1、血清素和血小板反应蛋白1（TSP-1）水平的差异。在可能的情况下，将冠心病患者分为急性冠状动脉综合征（ACS）和慢性冠状动脉疾病（CCD）。计算标准化平均差（SMD）。结果：由于研究存在异质性，我们对sCD40L、sGPV、MMP-9、PF4、sP-selectin、SCUBE1和TSP-1进行meta分析。与HS相比，CAD患者除TSP-1外的所有标志物均显著升高。sCD40L和SCUBE1的差异只有在合并血浆和血清研究时才有统计学意义。与HS相比，ACS与CCD在MMP-9 （SMD: 2.49 vs 0.49）、PF4 （SMD: 2.01 vs 0.96）和sp -选择素（SMD: 1.81 vs 0.63）方面的差异更大。sCD40L和ACS中sP-selectin和PF4均存在发表偏倚。结论：与HS相比，CAD患者的sCD40L、sGPV、MMP-9、PF4、sp -选择素和SCUBE1水平升高，为设计新的研究提供了理论依据，以解决这些分子作为血栓形成风险分层的生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thrombosis and Haemostasis 医学-外周血管病

CiteScore

24.30

自引率

3.80%

发文量

321

审稿时长

1 months

期刊介绍： The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community. Types of Publications: The journal publishes a variety of content, including: Original research reports State-of-the-art reviews Brief reports Case reports Invited commentaries on publications in the Journal Forum articles Correspondence Announcements Scope of Contributions: Editors invite contributions from both fundamental and clinical domains. These include: Basic manuscripts on blood coagulation and fibrinolysis Studies on proteins and reactions related to thrombosis and haemostasis Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.